Skip to main content

Healthcare BPO Market To Reach $312.43 Billion By 2022 : Increasing Consolidation In The Healthcare Industry

 What This Report Will Provide?

In the current market scenario, there is a growing demand for healthcare BPO services. The objective of this report is to define, describe, and forecast the market on the basis of outsourcing services including payer, provider, and pharmaceutical services and region. It provides detailed information regarding the major factors influencing the growth of healthcare outsourcing market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials.

Expected Revenue Growth:

Healthcare BPO market is estimated to grow at a CAGR of 10.2% from 2017 to 2022 to reach $312.43 billion by 2022 from $191.68 billion in 2017. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022.

Major Growth Boosters:

Patent cliffs, complex clinical trial protocols, and new reporting requirements are forcing pharmaceutical companies to outsource their R&D and manufacturing processes to other countries, which is driving the healthcare outsourcing market.

Download PDF Brochure:  https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=41882774 

Target Audience:

  • Vendors/Service Providers
  • Healthcare Service Providers
  • Health Insurance Companies
  • Business Research and Consulting Service Providers
  • Research Institutions

Based on provider services, the Healthcare BPO market is segmented into revenue cycle management, patient enrolment & strategic planning, and patient care. The revenue cycle management segment is expected to grow at the highest CAGR during the forecast period. Growth in the revenue cycle management market can largely be attributed to factors such as decreasing reimbursements in the healthcare industry, reductions in the overall healthcare costs, initiatives undertaken by governments for implementing RCM solutions, and increasing expenditure by the Healthcare IT industry.

Request Sample Report:  https://www.marketsandmarkets.com/requestsampleNew.asp?id=41882774 

On the basis of pharmaceutical services, is segmented into manufacturing services, R&D services, and non-clinical services. The non-clinical services segment is expected to account for the highest CAGR during the forecast period. Factors like pricing pressure and the requirement of large field forces have further contributed towards the emergence of contract sales organizations in the pharmaceutical industry.

Regional Growth Analysis:

The global healthcare consulting services market was dominated by North America, followed by Europe in 2017. Factors such as increasing M&A activity, pricing pressure on pharmaceutical companies are driving the growth of the healthcare consulting services market in this region. Asia Pacific, however, is estimated to register the highest CAGR during the forecast period due to the increasing need for remote care and telemedicine in rural areas in the region.

Comments

Popular posts from this blog

Healthcare BPO Market To Reach $312.43 Billion By 2022 : Increasing Consolidation In The Healthcare Industry

  What This Report Will Provide? In the current market scenario, there is a growing demand for healthcare BPO services. The objective of this report is to define, describe, and forecast the market on the basis of outsourcing services including payer, provider, and pharmaceutical services and region. It provides detailed information regarding the major factors influencing the growth of healthcare outsourcing market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials. Expected Revenue Growth: Healthcare BPO market  is estimated to grow at a CAGR of 10.2% from 2017 to 2022 to reach $312.43 billion by 2022 from $191.68 billion in 2017. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Major Growth Boosters: Patent cliffs, complex clinical trial protocols, and new reporting requirements are forcing pha...

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...

North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

  What This Report Will Provide? The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Expected Revenue Growth: [159 Pages Report] The  North American nuclear medicine market  is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. Major Growth Boosters: Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment...